44.93
-0.585(-1.29%)
Currency In USD
| Previous Close | 43.56 |
| Open | 43.52 |
| Day High | 45.55 |
| Day Low | 43.05 |
| 52-Week High | 45.56 |
| 52-Week Low | 14.8 |
| Volume | 705,119 |
| Average Volume | 1.01M |
| Market Cap | 3.41B |
| PE | -22.2 |
| EPS | -2.05 |
| Moving Average 50 Days | 40.76 |
| Moving Average 200 Days | 29.64 |
| Change | 1.95 |
CG Oncology Announces New Board Member and Board Transition
GlobeNewswire Inc.
3 hours ago
- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing an
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting
GlobeNewswire Inc.
Yesterday at 9:05 PM GMT
Two late-breaking podium presentations and three posters continue to demonstrate cretostimogene as a potential backbone therapy for a broad range of NMIBC patientsIRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
GlobeNewswire Inc.
Sep 05, 2025 11:00 AM GMT
- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) treatment -- 90% of 12-month r